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Abstract
Introduction Certain rare, familial mutations in the ATM,
BRCA1, BRCA2, CHEK2 or TP53 genes increase
susceptibility to breast cancer but it has not, until now, been
clear whether common polymorphic variants in the same genes
also increase risk.
Methods We have attempted a comprehensive, single
nucleotide polymorphism (SNP)- and haplotype-tagging
association study on each of these five genes in up to 4,474
breast cancer cases from the British, East Anglian SEARCH
study and 4,560 controls from the EPIC-Norfolk study, using a
two-stage study design. Nine tag SNPs were genotyped in
ATM, together with five in BRCA1, sixteen in BRCA2, ten in
CHEK2 and five in TP53, with the aim of tagging all other
known, common variants. SNPs generating the common amino
acid substitutions were specifically forced into the tagging set
for each gene.
Results No significant breast cancer associations were
detected with any individual or combination of tag SNPs.
Conclusion It is unlikely that there are any other common
variants in these genes conferring measurably increased risks of
breast cancer in our study population.
Introduction
Four of the genes which lie in the DNA damage-recognition
and repair pathway, ATM, BRCA1, BRCA2 and TP53, have
mutations that are recognised to increase breast cancer sus-
ceptibility with moderate to high penetrance. Such mutations
are very rare, and most probably of recent origin. A fifth gene,
CHEK2, in the same pathway, has a deletion (1100delC) that
reaches polymorphic frequencies (>0.01) in some European
countries and doubles the risk of breast cancer in female car-
riers [1]. Together these mutations account for only a small
proportion (2% to 5%) of all breast cancer incidences [2,3].
Breast cancer is, however, a common disease and genetic epi-
demiological data suggest that there is a low-penetrance
genetic contribution to most cases [4,5]. It is likely that at least
a part of breast cancer aetiology will fit the common disease-
common variant hypothesis, which states that patients with a
common, complex disease are likely to share some common,
low-penetrance alleles that increase their susceptibility to that
disease. This raises the question of whether such common,
polymorphic susceptibility alleles exist within these five genes
in addition to the rare, disease-causing mutations that are
already known.
It is now possible to attempt a comprehensive exclusion of all
common single nucleotide polymorphisms (SNPs) from asso-
ciation with breast cancer susceptibility, using an empirical tag
SNP approach. Studies have already been attempted in some
of these genes. In ATM, Tamimi and colleagues [6] examined
5 haplotype-tagging SNPs (htSNPs) in approximately 3,000
subjects from the Nurses Heath Study but found no associa-
tions with breast cancer risk. For BRCA1, Cox and colleagues
[7] used 4 htSNPs in the Nurses Health Study and identifiedPage 1 of 14
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(95% confidence interval (CI) 1.02 to 1.37), while Freedman
and colleagues [8] examined 9 SNP-tagging SNPs (stSNPs)
in the approximately 900 Caucasian subjects from the Multi-
Ethnic Cohort but found no significant effects. For BRCA2,
Freedman and colleagues [9] also used 21 stSNPs in the
Multi-Ethnic Cohort and found one (rs206340) to be associ-
ated with a homozygous increase in risk (OR = 1.59, 95% CI
1.18 to 2.16). In addition, numerous studies have examined
the N372H amino acid substitution in BRCA2 with conflicting
results [10-12]. In CHEK2, Einarsdottir and colleagues [13]
studied 6 htSNPs in approximately 3,000 Swedish cases and
controls but found no significant associations with breast can-
cer. No comprehensive tagging study has yet been carried out
for TP53, but several studies have examined the association of
the non-synonymous R72P change and again the results have
been mixed (reviewed in [14]).
We have used a combined SNP- and haplotype-tagging
approach in an attempt to mark all the common variants in
these five genes. Selected tag SNPs were then evaluated in
our East Anglian breast cancer case-control study. The princi-
pal hypothesis underlying this experiment is that one or more
common variants in these five genes are associated with an
altered risk of breast cancer. We therefore aimed to identify a
set of tag SNPs that efficiently captures all the known common
variation (minor allele frequency (MAF) > 0.05) and is, there-
fore, likely also to tag most of the unknown common variants.
This approach is most reliable where the gene has been re-
sequenced in a sample of individuals that is sufficiently large
to identify all common variants. We thus preferentially used re-
sequencing data from the Environmental Genome Project
(EGP) [15], but in genes where data was not available at the
commencement of our study, data from the HAPMAP project
[16] was used. HAPMAP does not re-sequence genes but
provides genotype data on a sufficiently dense set of SNPs in
samples of subjects from different ethnicities.
Our goal was to identify any common variants that show evi-
dence for association with breast cancer susceptibility or, fail-
ing that, to exclude the possibility that common variants in
these five genes are associated with an altered risk of breast
cancer.
Materials and methods
Patients and controls
Cases were drawn from the SEARCH (breast) collection, an
ongoing population-based study of breast cancer, with cases
ascertained through the Eastern Cancer Registry (formerly
East Anglian Cancer Registry). All patients diagnosed with
invasive breast cancer below age 55 years since 1991 and
still alive in 1996 (prevalent cases, median age 48 years),
together with all those diagnosed below age 70 years
between 1996 and the present (incident cases, median age
54 years), were eligible to take part. Of the eligible breast can-
cer patients, 67% returned a questionnaire and 64% provided
a blood sample for DNA analysis. Eligible patients who did not
take part in the study were similar to participants except, as
might be expected, the proportion of clinical stage III/IV cases
was somewhat higher in non-participants (Additional file 1).
Controls were randomly selected from the Norfolk component
of EPIC (European Prospective Investigation of Cancer). EPIC
is a prospective study of diet and cancer being carried out in
nine European countries. The EPIC-Norfolk cohort comprises
25,000 individuals resident in Norfolk, East Anglia, the same
region from which the cases have been recruited. Controls are
not matched to cases, but are broadly similar in age, being
aged 42 to 81 years. The ethnic background of both cases
and controls, as reported on the questionnaires, is similar, with
>98% being white. This study has been approved by the East-
ern Region Multicentre Research Ethics Committee, and all
participants gave written informed consent.
The total number of cases available for analysis was 4,474, of
which 27% were prevalent cases. The samples have been
split into two sets in order to save DNA and reduce genotyping
costs: the first set (n = 2,271 cases and 2,280 controls) is
genotyped for all SNPs and the second set (n = 2,203 cases
and 2,280 controls) is then tested for those SNPs that show
marginally significant associations in set 1 (P-heterogeneity or
P-trend <0.1). Cases were randomly selected for set 1 from
the first 3,500 recruited, with set 2 comprising the remainder
of these plus the next 974 incident cases recruited. As the
prevalent cases were recruited first, the proportion of preva-
lent cases was somewhat higher in set 1 than in set 2 (33%
versus 20%). Median age at diagnosis was similar in both sets
(51 and 52 years old, respectively). There was no significant
difference in the morphology, histopathological grade or clini-
cal stage of the cases by set or by prevalent/incident status.
Power
The statistical power of the study depends on the susceptibil-
ity allele frequency, the risks conferred and the genetic mode
of action (dominant, recessive, co-dominant). The staged
approach substantially reduces genotyping costs without sig-
nificantly affecting statistical power – a comparison is shown
in Additional file 2. For example, assuming that the causative
SNP is tagged with a pairwise correlation coefficient (rp2) of
0.8, a type I error rate of 0.0001 and a genotyping success
rate of 0.95, the staged/full study has 86/88% power to
detect a dominant allele with MAF = 0.05 that confers a rela-
tive risk of 1.5 or 87/89% power to detect a dominant allele
with MAF = 0.25 that confers a relative risk of 1.3. Power to
detect recessive alleles is less; 53/60% for an allele with MAF
= 0.25 and risk 1.5 and 71/75% for an allele with MAF = 0.5
and risk 1.3.
Selection of tagging SNPs
We attempted to define a set of tag SNPs such that all known
common SNPs in a gene had an estimated r2 > 0.8 with atPage 2 of 14
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measure of the extent to which one SNP tags another SNP is
the pairwise correlation coefficient (rp2), since the loss in
power incurred by using a marker SNP in place of a true causal
SNP is directly related to this measure. We aimed to define a
set of tagging SNPs such that all known common SNPs had
an estimated rp2 of >0.8 with at least one tagging SNP. How-
ever, some SNPs are poorly correlated with other single SNPs
but may be efficiently tagged by a haplotype defined by multi-
ple SNPs, thus reducing the total number of tag SNPs
needed. As an alternative, therefore, we aimed for a correlation
between each SNP and a haplotype of tag SNPs (r2S) of >0.8.
Since tag SNP selection is problematic if there is extensive
haplotype diversity, where necessary we divided a gene into
haplotype blocks and selected the tagging SNPs for each
block separately. It is possible to use a variety of formal defini-
tions of haplotype blocks, but we simply used the graphical
representations of the pattern of linkage disequilibrium (LD)
based on D' and selected blocks such that the common hap-
lotypes in each block accounted for at least 80% of all haplo-
types observed using the Haploview program.
This tag SNP approach is most reliable where the gene has
been re-sequenced in a sample of individuals that is suffi-
ciently large to identify all common variants. We preferentially
used data from the EGP [15], which has been re-sequencing
candidate genes for cancer across panels of individuals repre-
sentative of US ethnicities. The original panel (P1-PDR90) of
90 individuals consisted of 24 European Americans, 24 Afri-
can Americans, 12 Mexican Americans, 6 Native Americans
and 24 Asian Americans, but the ethnic group identifiers were
not available. It is known that there is greater genetic and hap-
lotype diversity in individuals of African origin. To reduce this
we have identified and excluded 28 of the samples with the
greatest African ancestry by comparing the genotypes of the
PDR-90 subjects with the genotypes of the National Heart
Lung and Blood Institute Variation Discovery Resource Project
African American Panel [15] for the same SNPs. Data from the
remaining 62 individuals were used to identify tag SNPs. For
CHEK2, where complete EGP data were not initially available,
data from European (CEU) subjects in HAPMAP were used as
an alternative [16].
The CHEK2 Del1100C mutation was too rare to be selected
as a tag SNP, or to be tagged in the current study, but it had
been previously assayed in the SEARCH cases and controls
[1] and those data have been incorporated here.
Taqman genotyping
Genotyping was carried out using Taqman® (Applied Biosys-
tems, Warrington, UK) according to the manufacturer's
instructions. Primers and probes were supplied directly by
Applied Biosystems as Assays-by-Design™. All assays were
carried out in 384-well plates. Cases and controls were
arranged in a chequerboard pattern on each plate to ensure
even treatment during the assay procedure and each plate
included negative controls (with no DNA) and positive controls
duplicated on a separate quality control plate. Plates were
read on the ABI Prism 7900 using the Sequence Detection
Software (Applied Biosystems). Failed genotypes were not
repeated. Assays in which the genotypes of duplicate samples
did not show >95% concordance were discarded and
replaced with alternative assays with the same tagging
properties.
Statistical methods
For each SNP, deviation of genotype frequencies in controls
from the Hardy-Weinberg equilibrium (HWE) was assessed
by a χ2 test with one degree of freedom. Genotype frequen-
cies in cases and controls were compared by χ2 test for heter-
ogeneity (two degrees of freedom) and test for trend (one
degree of freedom). Genotype specific risks were estimated
as ORs using unconditional logistic regression. Genotype dis-
tributions were also compared between prevalent and incident
cases and between subjects in set 1 and set 2 with χ2 tests
(two degrees of freedom). No statistically significant differ-
ences were found (data not shown) and so the results have
been combined. The tagSNPsv2 program [17] was used to
impute all the haplotypes generated by the tag SNPs in each
LD block and to estimate the probabilities of each subject car-
rying each of the common (>0.05) haplotypes. Rarer haplo-
type probabilities were pooled into a single category.
Haplotype frequencies were compared between cases and
controls and haplotype-specific risks were estimated as ORs
with associated CIs using unconditional logistic regression.
Results and discussion
SNP-tagging
ATM
The EGP identified 75 common variants in their set of 90
mixed-ethnicity subjects. After the exclusion of the 28 subjects
with most African ancestry, 69 SNPs suitable for study in our
European population remained. These fall into a single LD
block with no evidence for recombination hot-spots. A set of
nine tag SNPs were identified using the tagSNPsv2 program
[17] and all were successfully genotyped. Tagging details are
shown in Table 1.
BRCA1
The EGP identified 123 common variants, of which 113 were
suitable for study in our sets (Table 1). Again, these lie in a sin-
gle block of LD. A set of eight tag SNPs was identified but
three of these could not be made into Taqman® assays and no
others could be found to provide the same information (that is,
they are singletons). A further SNP appeared to be hyper-
mutable and it was not further investigated. Eventually, four tag
SNPs were successfully genotyped (Table 1). An additional
SNP, Q356R (BRCA1-02), was not selected as a tag SNP as
its MAF in EGP was below our threshold of 0.05, but it was
genotyped here because we had previously found somePage 3 of 14
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ian and breast cancer.
BRCA2
The EGP identified 113 common SNPs and 91 of these
remained for study after exclusion of the African subjects. The
BRCA2 block structure (Figure 1) is more complex than seen
in the other genes; the first ten SNPs show no clear block
structure and the remaining can be divided into two, largely
separate, blocks. Twenty-two tag SNPs were initially identified
but for six of these (all singletons) the local sequence pre-
cluded the manufacture of a working Taqman® assay and so
these could not be analysed here (Table 1).
CHEK2
At the commencement of this study this gene had not been re-
sequenced by EGP and so HAPMAP phase 1 data for the
Caucasians (CEPH trios) were used instead. HAPMAP had
genotypes for 30 SNPs with MAF > 0.05 and these fell into a
single LD block. Ten tag SNPs (Table 1), were successfully
genotyped. Previously published [1] data on a subset of these
subjects who were genotyped for the 1100delC variant are
also included for comparison (Table 2).
TP53
The EGP identified 46 common SNPs, of which 39 were suit-
able for study after exclusion of the African subjects. These lie
in a single LD block and are tagged with six SNPs. We set the
tagging parameters to include two SNPs that had been
selected for a previous study (TP53-01 (R72P, rs1042522)
and TP53-02 (rs1625895)). One SNP (rs17880722) could
not be made into a Taqman® assay and, since these were sin-
gletons, this left a final set of five tag SNPs that were geno-
typed (Table 1).
SNP associations
The genotype distributions for all SNPs genotyped in breast
cancer case-control set 1 are shown in the left-hand columns
of Table 2. In the BRCA1 and TP53 genes, no SNPs showed
suggestive association (p < 0.1) at this stage and none were
further investigated. One tag SNP in the ATM gene (ATM-08,
rs3092991), four in BRCA2 (BRCA2-04,-11,-13 and -21/
rs206118, rs11571686, rs1799955 and rs206343) and
three in CHEK2 (CHEK2-09,-11 and -14/rs2236141,
rs1076807 and rs9608698) provided sufficient evidence of
association to merit further evaluation in case-control set 2.
The genotype distributions of these SNPs in the entire study
(sets 1 and 2) are shown in the right-hand columns of Table 2.
After the completion of both stages, no tag SNP from ATM,
BRCA1, BRCA2 or TP53 was associated with a significant
difference in breast cancer risk.
The only SNP that was significantly associated (nominal
threshold of p < 0.05) after completion of stage 2 was
CHEK2-14 (rs9608698; P-trend = 0.02). This SNP was
associated with an increased risk of breast cancer in both het-
erozgotes (OR = 1.10; 95% CI 0.99 to 1.21) and rare
homozygotes (OR = 1.15; 95% CI 1.02 to 1.29) relative to the
common homozygotes.
We specifically chose to study SNPs that generate amino acid
substitutions and had been included in previously published
association studies. BRCA1 P271L (BRCA1-01,
rs1799917), BRCA2 N372H (BRCA2-22, rs144848) and
TP53 R72P (TP53-01, rs1042522) were included in the set
of tagging SNPs for their respective genes and it can be seen
Table 1
SNP tagging details and data for each gene
Gene SNP source Total SNPs 
with MAF > 
0.05
Total SNPs after 
exclusion of 
African subjects
No. of Tag 
SNPs selected 
for r2 > 0.8
Usable 
SNPs
No. of SNPs 
tagged with rp2 > 
0.8 (percent)
No. of SNPs 
tagged with rp2 > 
0.5 (percent)
No. of SNPs 
tagged with r2S > 
0.8 (percent)
ATM EGP 75 69 9 9 64 (92) 69 (100) 65 (94)
BRCA1 EGP 123 113 8 5 67 (59) 109 (96) 77 (68)
BRCA2 EGP 113 91 22 16 53 (58) 86 (95) 61 (67)
CHEK2 HAPMAP 30 N/A 10 10 16 (53) 20 (67) 22 (73)
TP53 EGP 46 39 6 5 24 (61) 35 (90) 31 (79)
EGP, NIEHS Environmental Genome Project; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Figure 1
Haploview output showing linkage disequilibrium relationships between the 91 ligible BRCA2 SNPs
the 91 eligible BRCA2 SNPs. The matrix indicates the D' value 
between each pair of SNPs – darker colours indicate higher values.Page 4 of 14
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Genotype distributions of all tag SNPS in case-control set 1 and the eligible ones in sets 1 and 2 combined
Set 1 Sets 1 and 2
SNP MAF Base 
change
Controls Cases Odds ratio (95 
percent CI)
HWE p 
value
Genotype 
frequency 
p value
Trend test 
p value
Controls Cases Odds ratio 
(95 percent 
CI)
Trend test 
p value
ATM
GG 1,881 1,808 1a
ATM-
04
0.09 GT 378 364 1.00 [0.86–1.17] 0.84 0.84 0.79
rs498
7876
TT 18 21 1.21 [0.64–2.29]
AA 707 694 1a
ATM-
05
0.44 AG 1,146 1,069 0.95 [0.83–1.09] 0.24 0.52 0.84
rs189
037
GG 420 427 1.04 [0.87–1.23]
AA 2,103 1,992 1a
ATM-
06
0.04 AG 169 183 1.14 [0.92–1.42] 0.19 0.47 0.29
rs223
4996
GG 6 5 0.88 [0.27–2.89]
AA 727 713 1a
ATM-
07
0.43 AG 1,147 1,058 0.94 [0.82–1.07] 0.14 0.37 0.80
rs599
164
GG 398 409 1.05 [0.88–1.24]
AA 1,627 1,611 1a 3,280 3,223 1a
ATM-
08
0.15 AG 606 553 0.92 [0.81–1.05] 0.03 0.09 0.06 1,193 1,081 0.92 [0.84–
1.01]
0.10
rs309
2991
GG 44 27 0.62 [0.38–1.01] 82 74 0.92 [0.67–
1.26]
GG 1,052 990 1a
ATM-
09
0.32 GA 1,000 971 1.03 [0.91–1.17] 0.48 0.70 0.41
rs665
293
AA 222 227 1.09 [0.89–1.33]
TT 712 688 1a
ATM-
10
0.43 TA 1,110 1,036 0.97 [0.84–1.11] 0.45 0.34 0.45
rs582
157
AA 405 426 1.09 [0.92–1.29]
CC 2,043 1,990 1a
ATM-
11
0.05 CT 214 183 0.88 [0.71–1.08] 0.01 0.35 0.15
rs180
0889
TT 13 9 0.71 [0.30–1.67]
GG 1,945 1,872 1a
ATM-
12
0.08 GA 310 300 1.01 [0.85–1.19] 0.02 0.48 0.64Page 5 of 14
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018
AA 22 14 0.66 [0.34–1.30]
BRCA1
P871l TT 1,001 939 1a
BRCA
1-01
0.33 TC 1,031 996 1.03 [0.91–1.17] 0.19 0.40 0.22
rs179
9917
CC 234 252 1.15 [0.94–1.40]
Q356
R
TT 2,004 1,955 1a 4,013 3,879 1a
BRCA
1-02
0.06 TC 256 221 0.89 [0.73–1.07] 0.13 0.15 0.08 511 469 0.95 [0.83–
1.08]
0.23
rs179
9950
CC 13 6 0.47 [0.18–1.25] 23 14 0.63 [0.32–
1.23]
TT 1,673 1,580 1a
BRCA
1-05
0.14 TC 553 568 1.09 [0.95–1.25] 0.87 0.45 0.38
rs817
6166
CC 47 42 0.95 [0.62–1.44]
TT 1,281 1,208 1a
BRCA
1-06
0.25 TG 857 851 1.05 [0.93–1.19] 0.69 0.68 0.65
rs817
6199
GG 137 127 0.95 [0.76–1.27]
GG 1,893 1,834 1a
BRCA
1-07
0.09 GA 362 337 0.96 [0.82–1.13] 0.31 0.53 0.38
rs373
7559
AA 22 15 0.70 [0.36–1.36]
BRCA2
TT 715 688 1a
BRCA
2-01
0.45 TC 1,083 1,057 1.01 [0.89–1.16] 0.08 0.72 0.62
rs206
115
CC 475 435 0.95 [0.81–1.13]
GG 870 813 1a 1,676 1,621 1a
BRCA
2-02
0.39 GA 1020 1,010 1.06 [0.93–1.21] 0.39 0.63 0.79 2,145 2,028 0.98 [0.89–
1.07]
0.95
rs206
116
AA 380 355 1.00 [0.84–1.19] 724 705 1.01 [0.89–
1.14]
GG 1,576 1,504 1a
BRCA
2-03
0.17 GA 628 601 1.00 [0.88–1.15] 0.96 0.64 0.58
rs309
2989
AA 63 71 1.18 [0.83–1.67]
AA 1,515 1,506 1a 3,046 2,943 1a
BRCA
2-04
0.19 GA 667 616 0.93 [0.81–1.06] 0.07 0.02 0.02 1,328 1,287 1.00 [0.92–
1.10]
0.29
rs206
118
GG 91 57 0.63 [0.45–0.88] 172 132 0.79 [0.63–
1.00]
Table 2 (Continued)
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BRCA
2-05
0.22 GA 763 719 1.03 [0.90–1.17] 0.09 0.75 0.98 1,594 1,486 1.00 [0.92–
1.10]
0.40
rs206
119
GG 102 86 0.92 [0.68–1.24] 203 216 1.14 [0.94–
1.40]
GG 1,263 1,189 1a
BRCA
2-07
0.25 GT 875 828 1.01 [0.89–1.14] 0.31 0.21 0.23
rs956
7552
TT 135 158 1.24 [0.98–1.59]
GG 612 626 1a 1,228 1,200 1a
BRCA
2-09
0.48 GA 1,137 1,082 0.93 [0.81–1.07] 0.46 0.22 0.08 2,317 2,189 0.97 [0.88–
1.07]
0.60
rs953
4174
AA 523 461 0.86 [0.72–1.02] 1,006 954 0.97 [0.86–
1.09]
CC 1,487 1,453 1a
BRCA
2-10
0.18 CT 669 620 0.95 [0.83–1.08] 0.62 0.63 0.73
rs212
6042
TT 70 74 1.08 [0.77–1.51]
AA 1,824 1,701 1a 3,609 3,434 1a
BRCA
2-11
0.10 AC 428 450 1.13 [0.97–1.31] 0.40 0.10 0.04 893 876 1.03 [0.92–
1.14]
0.28
rs115
71686
CC 25 35 1.50 [0.89–2.52] 52 63 1.27 [0.88–
1.84]
AA 1,422 1,290 1a 2,812 2,672 1a
BRCA
2-13
0.21 AG 761 776 1.12 [0.99–1.27] 0.70 0.03 0.01 1,548 1,491 1.01 [0.93–
1.11]
0.48
rs179
9955
GG 92 115 1.38 [1.04–1.83] 194 201 1.09 [0.89–
1.34]
GG 1,204 1,205 1a
BRCA
2-14
0.27 GA 907 833 0.92 [0.81–1.04] 0.83 0.26 0.10
rs115
1742
AA 167 145 0.87 [0.68–1.10]
AA 1,733 1,603 1a
BRCA
2-16
0.12 AG 484 414 0.92 [0.80–1.07] 0.33 0.56 0.43
rs494
2485
GG 34 33 1.05 [0.65–1.70]
CC 2,020 1,910 1a
BRCA
2-18
0.06 CA 235 253 1.14 [0.94–1.38] 6 × 10-5 0.27 0.11
rs115
71789
AA 19 24 1.34 [0.73–2.45]
AA 1,247 1,186 1a
BRCA
2-19
0.26 AG 829 820 1.04 [0.92–1.18] 0.11 0.83 0.63
rs542
551
GG 164 159 1.02 [0.81–1.29]
Table 2 (Continued)
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BRCA
2-21
0.22 AG 769 720 0.94 [0.83–1.07] 0.39 0.15 0.08 1,527 1,465 1.00 [0.92–
1.10]
0.54
rs206
343
GG 119 90 0.76 [0.57–1.01] 225 192 0.89 [0.73–
1.09]
N372
H
AA 1,149 1,109 1a 2,306 2,182 1a
BRCA
2-22
0.28 AC 942 896 0.98 [0.87–1.11] 0.07 0.96 0.78 1,892 1,824 1.02 [0.93–
1.11]
0.58
rs144
848
CC 171 161 0.97 [0.77–1.23] 339 333 1.04 [0.88–
1.22]
CHEK2
AA 914 857 1a
CHEK
2-05
0.37 AT 1,045 1,019 1.04 [0.92–1.18] 0.55 0.82 0.60
rs576
2760
TT 315 306 1.04 [0.86–1.24]
AA 1,296 1,243 1a
CHEK
2-06
0.25 AG 813 789 1.01 [0.89–1.15] 0.11 0.72 0.72
rs207
3327
GG 152 133 0.91 [0.71–1.17]
GG 1,554 1,548 1a
CHEK
2-07
0.17 GC 633 558 0.88 [0.77–1.01] 0.87 0.20 0.12
rs234
7443
CC 66 62 0.94 [0.66–1.34]
GG 1,150 1,130 1a
CHEK
2-08
0.29 GA 938 868 0.94 [0.83–1.07] 0.63 0.64 0.50
rs738
722
AA 182 175 0.98 [0.78–1.22]
GG 1,718 1,598 1a 3,439 3,199 1a
CHEK
2-09
0.13 GA 510 553 1.17 [1.02–1.34] 0.31 0.04 0.18 1,021 1,087 1.14 [1.04–
1.26]
0.07
rs223
6141
AA 41 29 0.76 [0.47–1.23] 86 69 0.86 [0.63–
1.19]
GG 1,235 1,198 1a
CHEK
2-10
0.26 GA 872 834 0.99 [0.87–1.12] 0.55 0.76 0.54
rs403
5540
AA 144 127 0.91 [0.71–1.17]
AA 1,914 1,885 1a 3,866 3,770 1a
CHEK
2-11
0.08 AT 331 281 0.86 [0.73–1.02] 0.71 0.22 0.10 633 563 0.91 [0.81–
1.03]
0.11
rs107
6807
TT 17 15 0.90 [0.45–1.80] 28 23 0.84 [0.48–
1.46]
GG 1,150 1,130 1a
CHEK
2-12
0.29 GA 928 851 0.93 [0.82–1.06] 0.87 0.54 0.47
Table 2 (Continued)
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7609
AA 184 178 0.98 [0.79–1.23]
GG 1,992 1,886 1a
CHEK
2-13
0.06 GA 270 2,866 1.12 [0.94–1.34] 0.19 0.38 0.17
rs175
08019
AA 5 7 1.48 [0.47–4.67]
CC 694 626 1a 1,410 1,249 1a
CHEK
2-14
0.45 CG 1,114 1,057 1.05 [0.92–1.21] 0.09 0.18 0.07 2,188 2,123 1.10 [0.99–
1.21]
0.02
rs960
8698
GG 463 488 1.17 [0.99–1.38] 940 956 1.15 [1.02–
1.29]
1100d
elCb
0.02 CC 0.90 2,887 2,671 1a 0.002
delC 14 34 2.63 [1.41–
4.90]
TP53
R72P GG 1,177 1,107 1a
TP53-
01
0.27 GC 854 768 0.96 [0.84–1.09] 0.52 0.75 0.48
rs104
2522
CC 166 148 0.95 [0.75–1.20]
CC 1,622 1,545 1a
TP53-
02
0.14 CT 520 449 0.91 [0.79–1.05] 0.09 0.39 0.20
rs162
5895
TT 55 48 0.92 [0.62–1.36]
CC 1,797 1,699 1a
TP53-
03
0.11 CG 438 453 1.09 [0.94–1.27] 0.04 0.45 0.41
rs228
7499
GG 39 34 0.92 [0.58–1.47]
AA 2,053 1,971 1a
TP53-
06
0.05 AG 217 204 0.98 [0.80–1.20] 0.77 0.91 0.94
rs178
87200
GG 5 6 1.25 [0.38–4.10]
CC 2,067 1,986 1a
TP53-
07
0.05 CT 204 198 1.01 [0.82–1.24] 0.99 0.81 0.76
rs178
86760
TT 5 7 1.46 [0.46–4.60]
CC 865 833 1a
TP53-
08
0.39 CT 1,069 1,022 0.99 [0.87–1.13] 0.69 0.95 0.89
rs989
3249
TT 342 336 1.02 [0.84–1.22]
Values in the minor allele frequency (MAF) and Hardy-Weinberg equilibrium (HWE) p value columns refer to controls only. aReference group. 
bAttempted in only 61% of subjects. CI, confidence interval.
Table 2 (Continued)
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association with breast cancer risk. A recent collaborative
study [18] has also investigated BRCA2 N372H in more than
31,000 subjects (cases and controls) as well as TP53 R72P
in almost 20,000 subjects. That study, similarly, found no main
effect with either amino acid substitution, although it did report
some evidence of BRCA2 HH homozygotes in the youngest
age groups having an increased risk of breast cancer. This
finding is compatible with the original two publications, which
reported a significantly increased risk of breast cancer in HH
homozygotes, since both had concentrated on very young
onset breast cancer cases [11,12].
We were unable to confirm the previously reported breast can-
cer association of BRCA1 Q356R (BRCA1-02, rs1799950).
The OR for the rare, RR, homozygote relative to the common,
QQ, group is 0.63 (95% CI 0.23 to 1.23; P-trend = 0.20, P-
recessive test = 0.18). This estimate is comparable with our
previous estimate, which was based on only 1,400 subjects
[19], but even this study, which is larger by 6 times, has <50%
power to test the hypothesis that this SNP is associated with
such a recessive protective effect (Additional file 2).
Haplotype associations
Some of the variants within these genes have not been well
tagged by an individual tag SNP, but a number of these have
been better covered by a combination (haplotype) of several
SNPs. Thus, the haplotypes predicted from the genotypes of
tag SNPs were also tested for association with breast cancer
risk; each common haplotype (predicted frequency >0.05) in
each LD block was tested individually, in addition to the effect
of the combined rarer haplotypes. The results are shown in
Table 3.
For TP53 four common haplotypes are predicted to be formed
from the five tag SNPS and none are significantly associated
with differences in breast cancer risk. For BRCA1 the five gen-
otyped SNPs generate five common haplotypes. Four of these
are not associated with differences in breast cancer risk. The
remaining one uniquely carries the R356 allele of the Q356R
polymorphism and its OR is thus very similar to that calculated
on the Q356R SNP analysis. For ATM, the eight tag SNPs
generate five common haplotypes. Four show no significant
association with breast cancer risk and the remaining one,
which uniquely carries the rare allele of ATM-08 (rs3092991),
displays a similar OR to that calculated by examination of this
SNP alone. Both the potential associations with BRCA1
Q356R and ATM rs3092992 were found to be false positives
after examination in stage 2 and the same conclusion can be
drawn about their haplotypes.
For BRCA2 the pattern is more complex and haplotypes were
analysed separately in the three LD blocks. In each block cer-
tain haplotypes gave results in set 1 that merited further inves-
tigation in set 2 (Table 3). Three further tag SNPs, in addition
to the five described in the previous section, were genotyped
in set 2 to enable the discrimination of these haplotypes. How-
ever, after stage 2, the potential associations with these hap-
lotypes had reduced in significance and so we can conclude
that they were also false positives.
Freedman and colleagues [9] reported that a haplotype of
BRCA2 tagged by SNP rs206340 was associated with a sig-
nificant increase in breast cancer risk among homozygotes
(OR aa/gg = 1.59; 95% CI 1.18 to 2.16)). In our study the
equivalent tag SNP was BRCA2-21 (rs206343; rp2 with
rs206340 = 0.89), which contrarily showed a non-significant
trend for the minor allele to decrease, rather than increase, risk
(Table 2; OR gg/aa = 0.89; 95% CI 0.73 to 1.09)].
Two haplotypes of CHEK2, both carrying the minor allele of
CHEK2-14 (rs9608698), showed potential associations but
with risks in opposing directions. These were evaluated further
by generating haplotypes from the SNP markers that had
already been taken into stage 2 as well as the 1100delC muta-
tion that had been typed for a previous study. The 1100delC
mutation, which has a frequency of 0.4% in these East Anglian
controls, is carried on a single haplotype that also carries
CHEK2-14. This rare haplotype is, as expected, significantly
associated with breast cancer susceptibility (OR = 2.66; 95%
CI 1.40 to 5.05) for the carrier versus the non-carrier, but
other, more common haplotypes tagged by CHEK2-14 but
not 1100delC also show marginal evidence for association
with differences in risk
Deviation from Hardy-Weinberg equilibrium
The coding region of the ATM gene has been reported to be
less polymorphic than other comparable genes, indicative of
constraint by Darwinian selection pressure [20]. The genotype
distribution of the BRCA2 N372H SNP has also previously
been noted to deviate from HWE [11,21], again indicating
possible selection. Here we note that there are more devia-
tions from HWE than would be expected by chance. The gen-
otype distributions of 11 of the 45 tag SNPs (24%) deviate
from HWE below the 10% significance level, and 5 (11%)
deviate below the 5% level, and 1 of these (BRCA2-18,
rs11571789) deviates with p = 6 × 10-5. All significant devia-
tions from HWE fall in just three of the five genes, ATM,
BRCA2 and TP53. Examination of the genotype clusters and
other quality control measures gives no indication that these
deviations are the result of genotyping artefacts. This leaves
open the possibility that common variants in these three genes
are subject to selection, acting either directly or indirectly via
selective sweep across other variants in LD with them.
Limitations
There are three classes of variant that we cannot be certain we
have excluded from association. The first class comprises
dominant alleles with MAF below 0.01 – these include the
known rare, disease-causing mutations in these five genes.Page 10 of 14
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Predicted haplotypes from the tagging SNPs for each gene and their association with breast cancer
Set 1 Sets 1 and 2
Gene Haplotype Frequency P value OR 95 percent CI Haplotype Frequency P value OR 95 percent CI
ATM
04,05,06,07,08,09,10,11,12 h010100100 0.30 0.2
h000001000 0.28 0.7
h000010000 0.14 0.05 0.9 0.78–0.99
h100000000 0.09 0.6
h010100101 0.07 0.9
h010100110 0.05 0.2
Combined rare 0.4
BRCA1
02,01,05,07,06 h00000 0.60 0.7
h01101 0.14 0.3
h01000 0.09 0.2
h01011 0.09 0.2
h10000 0.06 0.08 0.9 0.71–1.02
Combined rare 0.5
BRCA2
Block 1: 01,02,03,04,05 h10000 0.42 0.6 h_0_00 0.42 0.5
h01000 0.17 0.007 1.2 0.78–0.98 h_1_00 0.17 0.2
h01010 0.17 0.02 0.9 0.78–0.98 h_1_10 0.17 0.3
h00101 0.15 0.8 h_0_01 0.18 0.3
Combined rare 0.4
Block 2: 07,09,10,22,11 h01010 0.27 0.8 h_1_10 0.27 0.9
h01000 0.19 0.05 0.9 0.80–1.00 h_1_00 0.20 0.4
h00100 0.18 0.9
h10000 0.17 0.8 h_0_00 0.40 0.6
h10001 0.07 0.07 1.2 0.99–1.37 h_0_01 0.11 0.2Page 11 of 14
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Combined rare 0.4
Block 3: 13,14,16,18,19,21 h000010 0.27 0.6 h0____0 0.57 0.9
h000001 0.21 0.1 0.9 0.83–1.02 h0____1 0.22 0.5
h100000 0.15 0.04 1.1 1.01–1.27 h1____0 0.21 0.5
h010000 0.15 0.2
h011000 0.12 0.4
h100100 0.06 0.1 1.2 0.98–1.35
Combined rare 0.8
CHEK2
10,11,6,7,5,8,12,13,14,9 h0000000000 0.23 0.3 h_0______00 0.54 0.02 0.9 0.88–0.99
h1000111000 0.20 0.5
h0000000011 0.13 0.2 h_0______11 0.13 0.07 1.1 0.99–1.18
h0111000010 0.07 0.08 0.9 0.74–1.02 h_1______10 0.07 0.1 0.9 0.81–1.02
h0000111000 0.07 0.8
h0011000010 0.06 0.6 h_0______10 0.25 0.06 1.1 0.99–1.15
h0010000110 0.06 0.2
h0000100010 0.04 0.05 1.3 1.00–1.56
Combined rare 0.5 h_0______10 delC 0.004 0.003 2.7 1.40–5.05
TP53
03,01,02,06,07,08 h000000 0.42 0.8
h000001 0.28 0.9
h011000 0.11 0.3
h001001 0.05 0.2
Combined rare 0.4
All haplotypes with predicted frequencies of >0.05 in controls are shown individually. Rarer ones are combined. The single nucleotide polymorphism (SNP) IDs and 
their order are shown in the first column. CI, confidence interval; OR, odds ratio.
Table 3 (Continued)
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BRCA1 and 20 in BRCA2 (as well as many more variants of
unknown function), which, like SNPs, all result from single-
base substitutions, but are present only in single families. Sim-
ilarly, there are as yet unknown numbers of rare mutations in
the ATM gene that increase risk of breast cancer in hetero-
zygous carriers [23]. Some of these result from single base
substitutions and could be expected to be present in up to 3%
of our cases (for example, S49C) [24].
The second class comprises those SNPs that have MAF =
0.05 to 0.25 but are recessive in effect. For both the above
classes, we had insufficient statistical power, even with a sam-
ple size of more than 9,000 subjects, for exclusion of all vari-
ants by genetic association.
The third class comprises variants that are not well tagged by
any of our genotyped tag SNPs or their combined haplotypes.
As can be seen from Table 1, there are several of these, pre-
dominantly in the BRCA2 and CHEK2 genes. Such hard-to-
tag variants often lie outside LD blocks or are hyper-mutable.
The minor alleles of these SNPs do not share identity-by-
descent with other SNPs and so cannot be detected by asso-
ciation; they will only have an effect on breast cancer risk if
they are the functional and directly increase cancer
susceptibility.
Conclusion
There is ample evidence that rare mutations in each of the five
genes ATM, BRCA1, BRCA2, CHEK2 and TP53 cause
increased susceptibility to breast cancer in the families who
carry them, but we find no evidence for the existence of com-
mon, polymorphic susceptibility alleles in these genes. How-
ever, there remains good evidence that such alleles,
conforming to the common disease-common variant hypo-
thesis, do exist in other breast cancer susceptibility genes.
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